Terbinafine topical - Celtic Pharma

Drug Profile

Terbinafine topical - Celtic Pharma

Alternative Names: IDEA-067; TDT-067; Terbinafine cutaneous suspension

Latest Information Update: 11 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IDEA
  • Developer Celtic Pharma
  • Class Antifungals; Carrier proteins; Naphthalenes; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Onychomycosis

Most Recent Events

  • 11 May 2015 No recent reports on development identified - Phase-III for Onychomycosis in USA, Iceland and Germany (Topical)
  • 30 May 2013 Biomarkers information updated
  • 30 Jun 2012 Celtic Pharma completes a phase II trial for Onychomycosis in USA (NCT01790165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top